The Filing Desk

Amwell

AMWL · NYSE · Health Care · Financials, fiscal 2018 to 2025

AMWL · Last close · November 19, 2026
$10.69
Value Amwell yourself

Amwell's revenue fell 2.0% to $249 million in fiscal 2025. Its operating margin was −42.2%, up from −85.5% a year earlier. Free cash flow was −$66 million. The diluted share count rose 7.0%.

AMERICAN WELL CORPORATION Latest fiscal year ended December 31, 2025 10-K filed February 12, 2026 · 0001193125-26-048776 Updated
Revenue
$249M
2.0%
Operating margin
−42.2%
43.3 pts
Net income
−$96M
 
Free cash flow
−$66M
 
Return on equity
−35.4%
18.7 pts
Market cap
$183M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-20), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Amwell does

Amwell sells software that lets hospitals, health insurers and employers offer doctor visits and other care online. Its clients run the programs under their own names. Patients can see a doctor by video for urgent care, primary care, mental health and follow-ups, often by clicking a link with no app to download. Inside hospitals, the same software connects doctors with specialists, for example for stroke care or remote nursing, and Amwell sells carts and devices, called Carepoints, that turn screens into video stations.

Amwell earns most of its money from recurring subscription fees for its platform, plus related services and Carepoint sales. When a client needs clinicians, its affiliated network, Amwell Medical Group, supplies them in all 50 states. Its clients are concentrated: its largest, the insurer Elevance Health, accounted for 31% of revenue in 2025. It names Teladoc, Included Health, Microsoft, Amazon, Zoom and electronic health record companies such as Epic among its competitors.

At the end of 2025 Amwell served about 50 health plans covering more than 90 million people, and about 80 large US health systems. Its platform handled more than 4.5 million virtual visits that year. It had 562 full-time employees, most in the United States and the rest mainly in Ireland, Israel, Colombia and the UK.

Its biggest risks, as it describes them

  • A large share of its revenue comes from a few clients, led by Elevance Health, and losing one would hurt.
  • It has a history of losses and says it may never become profitable.
  • Online care is still a young market and may grow more slowly than it expects or draw bad publicity.
  • It faces strong competition from telehealth firms, big technology companies and health record providers.
  • Its work for the US military's Defense Health Agency may not continue on similar financial terms.
From Amwell's annual report on Form 10-K, filed February 12, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Amwell lost money in fiscal 2025: a net loss of $96 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments—538372228182
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio5.8x5.5x4.8x2.9x3.4x
Quick ratio5.8x5.4x4.7x2.8x3.4x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Amwell's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Amwell says to expect

  • Fourth quarter 2026: adjusted EBITDAQ4 adjusted EBITDA expected to in the range of $0 million to $1 million.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 3, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4,938 of Amwell shares on the open market, and 6 insiders sold $792,528, $98,882 of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 1, 2026Mark HirschhornChief Financial OfficerSold10,751$11.80$126,862Form 4
Sep 1, 2026Phyllis GotlibPresident, InternationalSold3,573$11.80$42,161Form 4
Sep 1, 2026Paul Francis McNeiceChief Accounting OfficerSold112$11.80$1,322Form 4
Jul 1, 2026Dmitry ZamanskyChief Product & Tech. OfficerSold8,460$9.33$78,932Form 4
Jul 1, 2026Phyllis GotlibPresident, InternationalSold6,677$9.33$62,296Form 4
Jul 1, 2026Mark HirschhornChief Financial OfficerSold4,299$9.33$40,110Form 4
Jul 1, 2026Paul Francis McNeiceChief Accounting OfficerSold653$9.33$6,092Form 4
Jun 11, 2026Stephen J. SchlegelDirectorSold plan9,750$8.76$85,410Form 4
Jun 1, 2026Mark HirschhornChief Financial OfficerSold10,761$9.74$104,812Form 4
Jun 1, 2026Phyllis GotlibPresident, InternationalSold3,573$9.74$34,801Form 4
Jun 1, 2026Paul Francis McNeiceChief Accounting OfficerSold112$9.74$1,091Form 4
May 7, 2026Ido SchoenbergChairman, co-CEO, DirectorBought670$7.37$4,938Form 4
The latest 12 of 25 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−63.9%−51.9%−28.4%
Altman Z''−9.04−12.18−16.00
Accruals ratio−58.3%−15.8%−7.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Amwell side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AmwellFY25−2.0%−42.2%−26.5%———
Omada HealthFY2553.2%−4.6%6.5%———Compare
HealthStreamFY254.3%6.7%19.6%———Compare
Health CatalystFY251.5%−51.7%−0.1%−38.6%—4Compare
HeartFlowFY2539.9%−36.4%−33.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue114149245253277259254249
Revenue growth—30.6%64.8%3.1%9.7%−6.5%−1.8%−2.0%
Gross profit————————
Research and development3654841071381068673
Operating income−55−95−227−179−276−692−218−105
Net income−53−87−224−176−270−675−208−96
Diluted EPS (US$)−26.00−42.40−45.40−13.80−19.72−47.50−13.88−5.96
Diluted shares (millions)2251314141516
Cash flow
Cash from operations−74−82−112−142−192−148−127−66
Capital expenditure21310000
Free cash flow−76−83−116−142−193−149−127−66
Dividends paid00000000
Share buybacks0038150100
Acquisitions644601560000
Stock-based compensation8121184468724822
Balance sheet at fiscal year end
Cash and short-term investments481781,042—538372228182
Debt incl. finance leases————————
Total assets—5001,3771,4461,218590436324
Total liabilities—12513018513411012076
Shareholders' equity−204−3071,2241,2391,064464305236
Margins and ratios
Gross margin————————
Operating margin−48.4%−63.6%−92.7%−70.9%−99.5%−267.2%−85.5%−42.2%
Net margin−46.2%−58.6%−91.5%−69.8%−97.6%−260.6%−81.8%−38.4%
Free cash flow margin−66.6%−55.9%−47.2%−56.2%−69.5%−57.3%−50.1%−26.5%
Rule of 40 (growth + FCF margin)—−25.3%17.6%−53.1%−59.8%−63.9%−51.9%−28.4%
Return on capital————————
Return on equity——−49.0%−14.3%−23.5%−88.4%−54.1%−35.4%
Return on assets——−23.9%−12.5%−20.3%−74.7%−40.6%−25.2%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Amwell's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Amwell.